Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.

Publication ,  Conference
Breslin, TM; Janjan, NA; Lee, JE; Pisters, PW; Wolff, RA; Abbruzzese, JL; Evans, DB
Published in: Front Biosci
November 1, 1998

Adjuvant 5-fluorouracil and concurrent radiation may improve survival following complete surgical resection in patients with pancreatic adenocarcinoma. However, the morbidity and prolonged recovery associated with pancreaticoduodenectomy frequently prevents the timely delivery of postoperative chemoradiation. Therefore, the University of Texas M.D. Anderson Cancer Center (MDACC) has investigated the use of neoadjuvant chemoradiation in potentially resectable pancreatic cancer. We have incorporated a standardized approach to pretreatment staging, operative technique and pathologic evaluation. Our initial experience suggests that preoperative chemoradiation is well tolerated and may reduce loco-regional recurrence. Patients treated with rapid-fractionation preoperative chemoradiation had a significantly shorter duration of treatment compared with patients who received postoperative chemoradiation or standard-fractionation preoperative chemoradiation. New and more potent radiation-sensitizing agents such as gemcitabine may further enhance local control. Novel therapies directed at specific molecular events involved in pancreatic tumorigenesis may be incorporated into preoperative and postoperative regimens to attempt to reduce systemic relapse.

Duke Scholars

Published In

Front Biosci

DOI

ISSN

1093-9946

Publication Date

November 1, 1998

Volume

3

Start / End Page

E193 / E203

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Survival Rate
  • Radiotherapy, Adjuvant
  • Radiation-Sensitizing Agents
  • Pancreaticoduodenectomy
  • Pancreatic Neoplasms
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Humans
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Breslin, T. M., Janjan, N. A., Lee, J. E., Pisters, P. W., Wolff, R. A., Abbruzzese, J. L., & Evans, D. B. (1998). Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. In Front Biosci (Vol. 3, pp. E193–E203). United States. https://doi.org/10.2741/a377
Breslin, T. M., N. A. Janjan, J. E. Lee, P. W. Pisters, R. A. Wolff, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” In Front Biosci, 3:E193–203, 1998. https://doi.org/10.2741/a377.
Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. In: Front Biosci. 1998. p. E193–203.
Breslin, T. M., et al. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.Front Biosci, vol. 3, 1998, pp. E193–203. Pubmed, doi:10.2741/a377.
Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DB. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Front Biosci. 1998. p. E193–E203.

Published In

Front Biosci

DOI

ISSN

1093-9946

Publication Date

November 1, 1998

Volume

3

Start / End Page

E193 / E203

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Survival Rate
  • Radiotherapy, Adjuvant
  • Radiation-Sensitizing Agents
  • Pancreaticoduodenectomy
  • Pancreatic Neoplasms
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Humans
  • Combined Modality Therapy